Masters Capital Management LLC bought a new stake in bluebird bio Inc (NASDAQ:BLUE) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 125,000 shares of the biotechnology company’s stock, valued at approximately $22,263,000. Masters Capital Management LLC owned approximately 0.25% of bluebird bio as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of BLUE. Meeder Asset Management Inc. boosted its holdings in bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after buying an additional 612 shares in the last quarter. NuWave Investment Management LLC purchased a new stake in bluebird bio during the fourth quarter worth about $135,000. Ladenburg Thalmann Financial Services Inc. raised its position in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 813 shares during the last quarter. Biondo Investment Advisors LLC acquired a new position in bluebird bio during the third quarter worth about $203,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in bluebird bio during the second quarter worth about $211,000.
A number of equities analysts have issued reports on the stock. BTIG Research lifted their target price on shares of bluebird bio to $250.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Canaccord Genuity reissued a “buy” rating and issued a $250.00 price objective on shares of bluebird bio in a research report on Tuesday, March 13th. Janney Montgomery Scott began coverage on shares of bluebird bio in a research report on Wednesday, March 14th. They issued a “neutral” rating and a $220.00 price objective for the company. BidaskClub lowered shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, UBS began coverage on shares of bluebird bio in a research report on Friday. They issued a “sell” rating for the company. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $192.35.
In related news, COO Susanna Gatti High sold 17,262 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total value of $3,381,798.42. Following the sale, the chief operating officer now directly owns 28,512 shares of the company’s stock, valued at $5,585,785.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Davidson sold 6,000 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $180.30, for a total transaction of $1,081,800.00. Following the completion of the sale, the insider now directly owns 21,977 shares in the company, valued at $3,962,453.10. The disclosure for this sale can be found here. Insiders sold 64,598 shares of company stock worth $12,370,309 over the last ninety days. 3.90% of the stock is currently owned by corporate insiders.
Shares of bluebird bio stock traded down $8.80 during mid-day trading on Monday, hitting $191.00. 519,935 shares of the stock traded hands, compared to its average volume of 823,255. The stock has a market capitalization of $9,986.71, a P/E ratio of -24.78 and a beta of 2.06. bluebird bio Inc has a fifty-two week low of $74.45 and a fifty-two week high of $236.17.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.84). The firm had revenue of $4.17 million during the quarter, compared to analysts’ expectations of $7.11 million. bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. bluebird bio’s revenue for the quarter was up 169.0% compared to the same quarter last year. During the same quarter last year, the company posted ($1.88) earnings per share. sell-side analysts anticipate that bluebird bio Inc will post -8.4 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “125,000 Shares in bluebird bio Inc (BLUE) Purchased by Masters Capital Management LLC” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/03/19/masters-capital-management-llc-takes-position-in-bluebird-bio-inc-blue.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.